Active Ingredient History
Glucarpidase (Voraxaze) is a medication used for the treatment of elevated levels of methotrexate during treatment of cancer patients who have impaired kidney function. Glucarpidase is an enzyme that inactivates methotrexate rapidly after injection. Because this agent reduces systemic levels of methotrexate and could therefore interfere with efficacy, it is not recommended for use in patients with normal or only slightly impaired kidney function or in whom serum levels are normal. The main antidote for methotrexate overdoses prior to the approval of this drug were high doses of folinic acid. However, this agent was not always sufficient at preventing kidney failure due to methotrexate. Glucarpidase also degrades folinic acid so the two should not be used together. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Methotrexate (approved 2012)
Dermatitis, Atopic (Phase 3)
Hematologic Neoplasms (Phase 1/Phase 2)
Kidney Diseases (Phase 1)
Leukemia (Phase 1)
Lymphoma (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Mucositis (Phase 1/Phase 2)
Neoplasms (Phase 2)
Osteosarcoma (Phase 2)
Skin Diseases (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
